M.D., Partner, 5AM Ventures
Biography
Brian Daniels joined 5AM Ventures as a Venture Partner in 2014 and transitioned to Partner in 2018. Dr. Daniels previously spent over two decades in clinical drug development, including leading the Development and Medical Affairs at Bristol-Myers Squibb for the last ten years. He directed the development of numerous innovative medicines that have contributed to the improvement for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ONGLYZA, FARXIGA and MYALEPT in metabolics, ELIQUIS in CV and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. Dr. Daniels is currently a board director for Artiva Biotherapeutics and Inipharm and was previously on the board of Cabaletta Bio (NASDAQ: CABA). He is on the Scientific Advisory Boards for Soteria and Ideaya Biosciences (NASDAQ: IDYA). Dr. Daniels received B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF
Session Abstract – PMWC 2023 Silicon Valley
Track 1 - January 26 9.00 A.M.-4.30 P.M.
Track Chair: Sharon Benzeno, Adaptive Biotechnologies
- PMWC 2023 Luminary Award Ceremony
Honoree: Bruce Levine, University of Pennsylvania
- Advance and Optimize Cell Therapies in Oncology (PANEL)
Chair: Sharon Benzeno, Adaptive Biotechnologies
- Ira Mellman, Genenetch
- Mark Selby, Walking Fish Therapeutics
- Sneha Ramakrishna, Stanford
- Loïc VINCENT, Affini-T Therapeutics
- Nick Haining, Arsenal
- Warner Biddle, Kite - Pioneering Cell Therapies in the Treatment of Autoimmune Disorders (PANEL)
Chair: Carl June, UPenn
- Lenny Dragone, Sonoma
- James Chung, Kyverna
- David Chang, Cabaletta
- Cristina Musselli, Abata Therapeutics - Innovations in Cell Therapy Manufacturing (PANEL)
Chair: Bruce Levine, University of Pennsylvania
- Chris Holt, BMS
- Heidi Hagen, Sonoma Bio
- Rahul Singhvi, Resilience
- Snehal Patel, Sana Biotechnology - Patentability of Immunotherapies - Latest Developments
- Janet Xiao, Morrison & Foerster LLP
- Investing in Gene-Modified Cell Therapies
Chair: Karen Tkach Tuzman, BioCentury Inc.
- Robert Lin, UPMC
- Yvonne Yamanaka, venBio
- Abraham Bassan, Samsara Capital
- Brian Daniels, 5am Ventures
- Leveraging Data Sets to Inform Future Drug Discovery and Development (PANEL)
Chair: Jason Coloma, Maze Therapeutics
- Peter DiLaura, Sonoma Bio
- Nick Haining, Arsenal
- Kwame Okrah, Parker Institute
- Dan Kirouac, Notch Therapeutics
